作者：董伟,董晓柳,石文健,刘永亮,李景武,张于,董桂兰,张欢,高华

单位：

1.063000 河北省唐山市人民医院神经外科　2.100070 北京市神经外科研究所细胞生物室

Units：

1.Departmenmt of Neurosurgery, Tangshan People's Hospital, Tangshan 063000, China 2.Cell Biology Room, Beijing Institute of Neurosurgery, Beijing 100070, China Corresponding author: GAO Hua, E-mail: huagao_bj@163.com

关键词：

垂体腺瘤; 细胞周期; 代谢; 治疗;

Keywords：

Pituitary adenoma; Cell cycle; Metabolism; Therapy

CLC：

DOI：

10.12114/j.issn.1008-5971.2021.00.290

Funds：

河北省自然科学基金精准医学联合基金细化项目（H2020105017）

摘要：

垂体腺瘤起源于垂体前叶,多为良性肿瘤,近年其发病率和患病率呈逐年增加趋势,约40%的手术治疗患者出现腺瘤切除不完全。除泌乳素腺瘤应用溴隐亭或卡麦角林治疗有效外,其他类型的垂体腺瘤药物治疗效果仍需进一步提高。了解垂体腺瘤的分子生物学特征可能会发现新的治疗方法。目前有氧糖酵解和线粒体功能障碍的具体分子机制尚未完全确定,但其是癌症发生发展的标志性事件。本文结合既往文献,基于细胞周期和代谢机制探讨垂体腺瘤的治疗策略,以期为垂体腺瘤临床诊治策略和肿瘤预后预测提供新的参考依据。

Abstract：

【Abstract】 Pituitary adenomas arise from the anterior pituitary and are usually benign, and the incidence andprevalence of pituitary adenomas are increasing in recent years, and approximately 40% of surgical patients have incompleteadenoma resection. In addition to the effective treatment of prolactin adenomas with bromocriptine or cabergoline, the therapeuticeffects of other types of pituitary adenomas still need to be further improved. Understanding the molecular biological characteristisof pituitary adenomas may lead to new treatments. At present, the specific molecular mechanisms of aerobic glycolysis andmitochondrial dysfunction have not been fully determined, but they are a landmark event in the occurrence and development ofcancer. This article combines the previous literature to review the therapeutic strategy of pituitary adenoma based on cell cycleand metabolism mechanism, in order to provide a reference basis for the clinical diagnosis and treatment of pituitary adenoma andtumor prognosis prediction.

ReferenceList：